Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available on ...

New Delhi: Accepting the bioequivalence study report for Type 2 Diabetes Mellitus, the Subject Expert Committee (SEC) ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

A global elderly and aging population has significant impacts, not only in terms of individual health risk but in terms of ...

ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...

India stands at a crossroads in the global clinical trials market. Despite its vast and diverse patient pool, cost-effective ...

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...